# PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE

> **NCT00499681** · PHASE2 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** lapatinib ditosylate
- **DRUG:** letrozole
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00499681
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2009-10
- **Final completion:** 2010-12
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2012-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00499681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00499681, "PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00499681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*